Gedeon Richter has become the latest firm to throw its hat into the ring for a denosumab biosimilar, after revealing that the European Medicines Agency has accepted for review the firm’s two marketing authorization applications for proposed rivals to Prolia and Xgeva.
Richter said its two MAAs “include all indications covered by the reference biologics,” such as treating osteoporosis in postmenopausal women,...






